Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

The Value of Tumor Treating Fields in Glioblastoma

  • Zhang, Chaochao (Department of Neurosurgery, First Hospital of Jilin University) ;
  • Du, Jianyang (Department of Neurosurgery, The Second Affiliated Hospital, Harbin Medical University) ;
  • Xu, Weidong (Department of Neurosurgery, First Hospital of Jilin University) ;
  • Huang, Haiyan (Department of Neurosurgery, First Hospital of Jilin University) ;
  • Gao, Li (Department of Outpatient, First Hospital of Jilin University)
  • Received : 2019.11.06
  • Accepted : 2020.01.23
  • Published : 2020.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Glioblastoma (GBM) is one of the most common tumors of the central nervous system, which is the most lethal brain cancer. GBM treatment is based primarily on surgical resection, combined with radiotherapy and chemotherapy. Despite the positive treatment, progression free survival and overall survival were not significantly prolonged because GBM almost always recurs. We are always looking forward to some new and effective treatments. In recent years, a novel treatment method called tumor treating fields (TTFields) for cancer treatment has been proposed. TTFields devices were approved by the Food and Drug Administration (FDA) for adjuvant treatment of recurrent and newly diagnosed GBMs in 2011 and 2015, respectively. This became the first breakthrough treatment for GBM in the past 10 years after the FDA approved bevacizumab for patients with relapsed GBM in 2009. This paper summarized the research results of TTFields in recent years and elaborated the mechanism of action of TTFields on GBM, including cell and animal experimental research, clinical application and social benefits.

Keywords

References

  1. Barnes FS, Greenebaum B : Handbook of Biological Effects of Electromagnetic Fields, ed 3. Boca Raton : CRC Press, 2006
  2. Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X : The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18 : 1129-1136, 2016 https://doi.org/10.1093/neuonc/now102
  3. Ciombor DM, Aaron RK : The role of electrical stimulation in bone repair. Foot Ankle Clin 10 : 579-593, vii, 2005 https://doi.org/10.1016/j.fcl.2005.06.006
  4. Clague DS, Wheeler EK : Dielectrophoretic manipulation of macromolecules: the electric field. Phys Rev E Stat Nonlin Soft Matter Phys 64(2 Pt 2) : 026605, 2001 https://doi.org/10.1103/PhysRevE.64.026605
  5. DeWitt JC, Mock A, Louis DN : The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol 30 : 643-649, 2017 https://doi.org/10.1097/WCO.0000000000000490
  6. Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, et al. : Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers (Basel) 11 : 174, 2019 https://doi.org/10.3390/cancers11020174
  7. Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, et al. : Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 5 : 18046, 2015 https://doi.org/10.1038/srep18046
  8. Gonzalez CF, Remcho VT : Harnessing dielectric forces for separations of cells, fine particles and macromolecules. J Chromatogr A 1079 : 59-68, 2005 https://doi.org/10.1016/j.chroma.2005.03.070
  9. Gutin PH, Wong ET : Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. Am Soc Clin Oncol Educ Book 32 : 126-131, 2012 https://doi.org/10.14694/EdBook_AM.2012.32.122
  10. Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr : Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J Med Econ 22 : 1006-1013, 2019 https://doi.org/10.1080/13696998.2019.1614933
  11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005 https://doi.org/10.1056/NEJMoa043331
  12. Hondroulis E, Melnick SJ, Zhang X, Wu ZZ, Li CZ : Electrical field manipulation of cancer cell behavior monitored by whole cell biosensing device. Biomed Microdevices 15 : 657-663, 2013 https://doi.org/10.1007/s10544-013-9788-2
  13. Jo Y, Kim EH, Sai S, Kim JS, Cho JM, Kim H, et al. : Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy. Int J Mol Sci 19 : 3684, 2018 https://doi.org/10.3390/ijms19113684
  14. Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, et al. : Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. Oncogene 38 : 6630-6646, 2019 https://doi.org/10.1038/s41388-019-0882-7
  15. Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. : Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 104 : 10152-10157, 2007 https://doi.org/10.1073/pnas.0702916104
  16. Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. : Disruption of cancer cell replication by alternating electric fields. Cancer Res 64 : 3288-3295, 2004 https://doi.org/10.1158/0008-5472.CAN-04-0083
  17. Kirson ED, Schneiderman RS, Dbaly V, Tovarys F, Vymazal J, Itzhaki A, et al. : Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 9 : 1, 2009 https://doi.org/10.1186/1756-6649-9-1
  18. Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, et al. : Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol 10 : 42, 2019 https://doi.org/10.3389/fneur.2019.00042
  19. Magouliotis DE, Asprodini EK, Svokos KA, Tasiopoulou VS, Svokos AA, Toms SA : Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. Acta Neurochir (Wien) 160 : 1167-1174, 2018 https://doi.org/10.1007/s00701-018-3536-6
  20. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. : CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 Suppl 2 : ii1-ii56, 2013
  21. Salzberg M, Kirson E, Palti Y, Rochlitz C : A pilot study with very lowintensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie 31 : 362-365, 2008 https://doi.org/10.1159/000137713
  22. Silginer M, Weller M, Stupp R, Roth P : Biological activity of tumortreating fields in preclinical glioma models. Cell Death Dis 8 : e2753, 2017 https://doi.org/10.1038/cddis.2017.171
  23. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. : Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318 : 2306-2316, 2017 https://doi.org/10.1001/jama.2017.18718
  24. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. : Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314 : 2535-2543, 2015 https://doi.org/10.1001/jama.2015.16669
  25. Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group : High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5 : v190-v193, 2010 https://doi.org/10.1093/annonc/mdq187
  26. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. : NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48 : 2192-2202, 2012 https://doi.org/10.1016/j.ejca.2012.04.011
  27. Swanson KD, Lok E, Wong ET : An overview of alternating electric fields therapy (NovoTTF Therapy) for the treatment of malignant glioma. Curr Neurol Neurosci Rep 16 : 8, 2016 https://doi.org/10.1007/s11910-015-0606-5
  28. Tuszynski JA, Wenger C, Friesen DE, Preto J : An overview of sub-cellular mechanisms involved in the action of TTFields. Int J Environ Res Public Health 13 : 1128, 2016 https://doi.org/10.3390/ijerph13111128
  29. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. : Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 : 2715-2722, 2006 https://doi.org/10.1200/JCO.2005.04.6078
  30. Wong ET, Lok E, Swanson KD : Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Cancer Med 4 : 383-391, 2015 https://doi.org/10.1002/cam4.421

Cited by

  1. The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway vol.12, 2020, https://doi.org/10.3389/fphar.2021.749242
  2. Tumor Treating Fields : Additional Mechanisms and Additional Applications vol.64, pp.3, 2020, https://doi.org/10.3340/jkns.2020.0188
  3. Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates vol.168, 2020, https://doi.org/10.1016/j.critrevonc.2021.103535
  4. Mechanisms involved in the anti-tumor effects of Toosendanin in glioma cells vol.21, pp.1, 2020, https://doi.org/10.1186/s12935-021-02186-2